Skip to main content

Table 1 Demographic and disease characteristics for all patients at WD and stratified by flare status

From: Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept

 

Flare status at WD+6mo

Flare status at WD+12mo

Overall

Characteristic at WD

Flare

(n = 100)

No flare

(n = 72)

P

Flare

(n = 113)

No flare

(n = 59)

P

N = 172

Age, yearsa

45.3 (12.7)

46.7 (11.9)

0.4757

45.4 (12.4)

46.8 (12.2)

0.4930

45.9 (12.3)

Weight, kga

69.9 (14.3)

73.3 (15.9)

0.1403

70.0 (13.7)

73.9 (17.2)

0.1426

71.3 (15.1)

Female, n (%)a

78 (78.0)

53 (73.6)

0.5051

88 (77.9)

43 (72.9)

0.4655

131 (76.2)

White, n (%)a

89 (89.0)

55 (76.4)

0.0271

99 (87.6)

45 (76.3)

0.0558

144 (83.7)

RA symptom duration, yearsa

0.6 (0.6)

0.5 (0.4)

0.0463

0.6 (0.5)

0.5 (0.4)

0.3325

0.5 (0.5)

RF+, n (%)

88 (88.0)

59 (81.9)

0.6360

100 (88.5)

47 (79.7)

0.4063

166 (96.5)

ACPA+, n (%)

93 (93.0)

64 (88.9)

0.9511

105 (92.9)

52 (88.1)

0.9880

161 (93.6)

TJC (of 28 joints)

0.4 (0.8)

0.4 (0.6)

0.4475

0.4 (0.8)

0.4 (0.6)

0.4547

21.9 (14.6)

n = 171

SJC (of 28 joints)

0.2 (0.7)

0.5 (1.1)

0.0305

0.3 (0.8)

0.4 (1.1)

0.3844

15.7 (12.0)

n = 171

CRP, mg/mL

4.1 (5.7)

3.2 (4.1)

0.2442

3.9 (5.5)

3.3 (4.4)

0.4648

14.6 (19.8)

Physician Global Assessment, VAS 0–100 mm

4.5 (7.0)

5.0 (7.4)

0.6912

4.8 (7.2)

4.5 (7.1)

0.7858

57.0 (18.9)

n = 170

HAQ-DI score (total score 0–3)

0.5 (0.5)

n = 94

0.3 (0.4)

n = 65

0.0088

0.4 (0.5)

n = 107

0.2 (0.4)

n = 52

0.0095

1.3 (0.7)

n = 161

Pain, VAS 0–100 mm

14.6 (14.4)

n = 94

13.2 (15.4)

n = 66

0.5422

14.1 (14.0)

n = 107

13.9 (16.5)

n = 53

0.9340

58.3 (20.0)

n = 161

Patient Global Assessment, VAS 0–100 mm

12.1 (14.7)

11.0 (13.5)

0.6092

11.6 (14.3)

11.7 (14.2)

0.9681

57.3 (21.5)

n = 167

Physical function, SF-36

77.8 (19.7)

80.7 (23.4)

0.3733

78.0 (19.9)

80.9 (24.0)

0.3879

42.8 (25.7)

n = 161

DAS28(CRP)

1.8 (0.4)

1.8 (0.5)

0.8519

1.8 (0.4)

1.8 (0.5)

0.8144

1.8 (0.4)

Treatment group, n (%)

       

  Abatacept + MTX

41 (41.0)

29 (40.3)

0.9928

47 (41.6)

23 (39.0)

0.9270

70 (40.7)

  Abatacept

28 (28.0)

21 (29.2)

0.8905

30 (26.5)

19 (32.2)

0.4793

49 (28.5)

  MTX

31 (31.0)

22 (30.6)

 NR

36 (31.9)

17 (28.8)

 NR

53 (30.8)

MRI synovitis score (total score 0–21)

3.7 (2.7)

n = 92

2.7 (2.1)

n = 63

0.0070

3.7 (2.6)

n = 103

2.6 (2.1)

n = 52

0.0107

NR

MRI erosion score (total score 0–230)

7.6 (6.1)

n = 92

4.4 (3.7)

n = 63

<0.0001

7.4 (6.0)

n = 103

4.3 (3.6)

n = 52

0.0001

NR

MRI bone edema score (total score 0–69)

2.1 (3.9)

n = 92

0.6 (1.1)

n = 63

0.0007

2.0 (3.8)

n = 103

0.6 (1.0)

n = 52

0.0004

NR

MRI unweighted combined inflammation scoreb

5.8 (5.8)

n = 92

3.3 (2.7)

n = 63

0.0003

5.6 (5.6)

n = 103

3.1 (2.6)

n = 52

0.0002

NR

MRI weighted combined inflammation scorec

8.0 (9.5)

n = 92

3.9 (3.5)

n = 63

0.0003

7.6 (9.1)

n = 103

3.7 (3.3)

n = 52

0.0002

NR

  1. Values are mean (standard deviation) unless indicated otherwise. P value for continuous variables is from a Student’s t test for equality of means. P value for categorical variables is from a chi-square test
  2. aIndicates data was collected at Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study baseline (not WD)
  3. bSynovitis score + edema score
  4. cSynovitis score + 2x edema score
  5. ACPA anti-citrullinated protein antibody, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, HAQ-DI Health Assessment Questionnaire–Disability Index, mo months, MRI magnetic resonance imaging, MTX methotrexate, NR not relevant, RA rheumatoid arthritis, RF rheumatoid factor, SJC(28) Swollen 28-Joint Count, SF-36 Short Form-36 subscale (0–100 scale), TJC(28) Tender 28-Joint Count, VAS visual analog scale, WD withdrawal
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us